

 <p>UniSR Università Vita-Salute San Raffaele</p>	<p>APPLICATION TO ACT AS SUPERVISOR AND RESEARCH PROJECT PROPOSAL</p>	<p>MO 20-5 ed. 02 of 16/01/2026 PO 20 Page 5 of 11</p>
---	--	---

PROJECT

Supervisor:

Cinthia Farina

Title:

Checkpoints for CNS inflammation

Curriculum:

Neurosciences and Experimental Neurology

Link to the personal page of the University or relevant hospital site website:

<https://research.hsr.it/en/institutes/institute-of-experimental-neurology/immunobiology-of-neurological-disorders.html>

Description of the Project (max 3,000 characters including spaces)

Background/gap of knowledge

Multiple Sclerosis (MS) is the most common cause of neurological disability in young adults. It is a chronic inflammatory disorder of the central nervous system (CNS) characterized by demyelination, inflammation and neuroaxonal damage. To counteract MS, therapies must target the immune system- to reduce inflammation- and the nervous system- to limit neurodegeneration and demyelination and promote repair. As current MS therapies mainly target the peripheral immune system, there is an unmet need for treatments that act on the nervous system to limit neurodegeneration and demyelination. Central to lesion maintenance is the scar tissue, mainly constituted by astrocytes.

Rationale and hypothesis

Astrocytes are the most abundant glia cell type of the CNS and are essential for tissue homeostasis, e.g. they provide metabolites and growth factors to neurons, participate in blood brain barrier maintenance and control immune cell trafficking and activation. Upon CNS injury they undergo morphological, molecular, and functional remodeling that may promote or dampen neuronal damage, demyelination and inflammation. Our lab has provided seminal descriptions about how these glia cells are reacting to several stimuli leading to complex networks of intracellular events within the scar in multiple sclerosis. On the other hand, distinct activation modes may share signaling steps and effector mechanisms, opening the way to the identification of central glial checkpoints amenable for therapeutic targeting. Our hypothesis is that checkpoints for CNS neuroinflammation exist and may be used to modulate CNS pathology.



Objectives and specific aims

The main objective is the identification of key signaling checkpoints in the astrocyte contributing to CNS neuroinflammation. The first specific aim is the identification of potential glial markers, regulators and processes associated with disease. Here, the analysis of available transcriptomics data relative to distinct compartments, including CNS, and to distinct types of CNS lesions and cells (ref.4), may lead to the description of checkpoints altered under disease for the astrocyte and other cell types in MS. The second specific aim regards the assessment of the contribution of the molecular checkpoint to key astrocyte functions for scar formation and tissue degeneration. Here, in vitro studies will evaluate whether genetic and/or pharmacological approaches targeting the checkpoint will affect processes such as glial proliferation, migration, production of inflammatory and toxic mediators, and eventually, the downstream impact on other cell types (e.g. neurons). Finally, the third specific aim will determine the role of the checkpoint on disease expression in relevant in vivo models.

Expected outcomes

Identification of potential glial checkpoints

Impact of checkpoints on cell function and cell-cell interaction.

Disease expression in experimental mouse models upon modulation of the checkpoint.

Skills that the student should acquire (max. 600 characters including spaces):

Advanced knowledge of Neurobiology, Immunology, Pathology, Molecular Biology, Histology, Transcriptomics, Bioinformatics.

Logical thinking, Scientific English.

References (max. 15)

1. Claudia Bassani, Marta Molinari, Valentina Romeo, Vittorio Martinelli, Ursula Boschert, Gianvito Martino, Luca Muzio and Cinthia Farina. *The contribution of BTK signalling in myeloid cells to neuroinflammation*. Front. Immunol 2025.
2. Emanuela Colombo, Marco Bacigaluppi, Michela Bartocchetti, Daniela Triolo, Claudia Bassani, Andrea Bergamaschi, Helene Deschamps, Giorgia Serena Gullotta, Maria Henley, Marco Piccoli, Luigi Anastasia, David Pitt, Jia Newcombe, Gianvito Martino and Cinthia Farina. *Astrocyte TrkB fosters brain injury and edema formation in ischemic stroke*. Neurobiol Disease 201, 2024.
3. Maryam Omrani, Rosaria Rita Chiarelli, Massimo Acquaviva, Claudia Bassani, Gloria Dalla Costa, Federico Montini, Paolo Preziosa, Francesca Grassivaro, Simone Guerrieri, Marzia Romeo, Francesca Sangalli, Bruno Colombo, Lucia Moiola, Mauro Zaffaroni, Anna Pietroboni, Alessandra Protti, Marco Puthenparampil, Roberto Bergamaschi, Giancarlo Comi, Maria A. Rocca, Vittorio Martinelli, Massimo Filippi, Cinthia Farina. *Machine learning-driven diagnosis of multiple sclerosis from whole blood transcriptomics*. Brain Behavior Immunity 121, 2024.



4. Sandra Abdullatef and Cinthia Farina. *Publicly available ex vivo transcriptomics datasets to explore CNS physiology and neurodegeneration: state of the art and perspectives*. *Frontiers in Neuroscience* 17, 2023.
5. Emanuela Colombo, Marco Di Dario, Ramesh Menon, Valente Maria Maddalena, Claudia Bassani, Nicole Sarno, Davide Mazza, Federico Montini, Lucia Moiola, Giancarlo Comi, Vittorio Martinelli and Cinthia Farina. *HNF4 α , SPI and c-myc are master regulators of CNS autoimmunity*. *Journal of Autoimmunity* 138, 2023.
6. Emanuela Colombo and Cinthia Farina. *Lessons from SIP receptor targeting in multiple sclerosis*. *Pharmacology and Therapeutics* 230, 2022.
7. Emanuela Colombo, Daniela Triolo, Bassani Claudia, Francesco Bedogni, Marco Di Dario, Giorgia Dina, Evelien Fredrickx, Isabella Fermo, Vittorio Martinelli, Jia Newcombe, Carla Taveggia, Angelo Quattrini, Giancarlo Comi and Cinthia Farina. *Dysregulated copper transport in multiple sclerosis may cause demyelination via astrocytes*. *PNAS* 118, 2021.
8. Massimo Acquaviva, Ramesh Menon, Marco Di Dario, Gloria Dalla Costa, Marzia Romeo, Francesca Sangalli, Bruno Colombo, Lucia Moiola, Vittorio Martinelli, Giancarlo Comi, Cinthia Farina. *Inferring Multiple Sclerosis stages from blood transcriptome via machine learning*. *Cell Rep. Med.* 1, 2020.
9. Martina Severa, Fabiana Rizzo, Sundararajan Srinivasan, Marco Di Dario, Elena Giacomini, Maria Chiara Buscarinu, Melania Cruciani, Marilena P. Etna, Silvia Sandini, Rosella Mechelli, Antonella Farina, Pankaj Trivedi, Paul J. Hertzog, Marco Salvetti, Cinthia Farina, Eliana M. Coccia. *A cell type-specific transcriptomic approach to map B cell and monocyte type I Interferon-linked pathogenic signatures in Multiple Sclerosis*. *J. Autoimmunity* 101: 1, 2019
10. Sundararajan Srinivasan, Marco Di Dario, Alessandra Russo, Ramesh Menon, Elena Brini, Marzia Romeo, Francesca Sangalli, Gloria Dalla Costa, Mariaemma Rodegher, Marta Radaelli, Lucia Moiola, Daniela Cantarella, Enzo Medico, Gianvito Martino, Roberto Furlan, Vittorio Martinelli, Giancarlo Comi, Cinthia Farina. *Dysregulation of multiple sclerosis risk genes and pathways at distinct stages of disease*. *Neurology: Neuroimmunol. Neuroinflamm.* 4 (3): e337, 2017.
11. Sundararajan Srinivasan, Martina Severa, Fabiana Rizzo, Ramesh Menon, Elena Brini, Rosella Mechelli, Vittorio Martinelli, Paul Hertzog, Marco Salvetti, Roberto Furlan, Gianvito Martino, Giancarlo Comi, Eliana Coccia, Cinthia Farina. *Transcriptional dysregulation of Interferome in experimental and human Multiple Sclerosis*. *Scientific Reports* 7:8981, 2017.
12. Di Dario Marco, Colombo Emanuela, Govi Chiara, De Feo Donatella, Messina Maria Josè, Romeo Marzia, Sangalli Francesca, Moiola Lucia, Rodegher Mariaemma, Martino Gianvito, Martinelli Vittorio, Comi Giancarlo and Farina Cinthia. *Myeloid cells as target of fingolimod action in multiple sclerosis*. *Neurology: Neuroimmunol. & Neuroinfl.* 2: e157, 2015.
13. Emanuela Colombo, Marco Di Dario, Eleonora Capitulo, Linda Chaabane, Jia Newcombe, Gianvito Martino and Cinthia Farina. *Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide*. *Annals Neurol.* 76 2014.
14. Ramesh Menon, Marco Di Dario, Chiara Cordiglieri, Silvia Musio, Loredana La Mantia, Clara Milanese, Anna Luisa Di Stefano, Massimo Crabbio, Diego Franciotta, Roberto Bergamaschi, Rosetta Pedotti, Enzo Medico and Cinthia Farina. *Gender-based blood transcriptomes and interactomes in multiple sclerosis: Involvement of SPI dependent gene transcription*. *J. Autoimmunity* 38, 2012.
15. Emanuela Colombo, Chiara Cordiglieri, Giorgia Melli, Jia Newcombe, Markus Krumbholz, Luis Parada, Enzo Medico, Reinhard Hohlfeld, Edgar Meinel and Cinthia Farina. *Stimulation of the neurotrophin receptor TrkB on astrocytes drives nitric oxide production and neurodegeneration*. *J.Exp. Med.* 209, 2012.